[A24-22] Talazoparib (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 15.05.2024
Project no.:
A24-22
Commission:
Commission awarded on 07.02.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated
Result of dossier assessment:
- Patients with treatment-naive mCRPC without HRR mutation: hint of lesser benefit
- Patients with treatment-naive mCRPC with HRR mutation: added benefit not proven
- Patients with pretreated mCRPC: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-22_en
| Project no. | Title | Status |
|---|---|---|
| A20-48 | Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |